Search

everythinglearnresearchcommunity

for

Search:↓

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

Cochrane and non-Cochrane drug safety reviews report well in PRISMA but poorly in PRISMA harms, with non-Cochrane needing improvement.

Baricitinib helped treat a man's beard hair loss when steroids didn't work.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

The rib-sparing technique in breast reconstruction may lead to more complications without reducing the need for further surgery.

Finasteride increased hair count and regrowth in men with hair loss but also caused more sexual side effects than placebo.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

New drugs for rheumatoid arthritis show improvement but have side effects and are not a cure.

The rib-sparing technique in breast reconstruction may lead to more complications without reducing the need for further surgery.

Dutasteride for hair loss might increase the risk of a rare stroke type.

Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.

JAK inhibitors show promise for treating various skin disorders effectively and safely.

Tiny particles carrying roxithromycin can effectively target and deliver the drug to hair follicles without irritation.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.

Ranitidine and finasteride lower TMAO levels, reducing heart and kidney damage by changing gut bacteria.

Upadacitinib effectively treats pyoderma gangrenosum.

The UK High Court revoked Lundbeck's patent for Escitalopram, and second medical use claims based on dosage were not considered novel.

HVDRR is caused by VDR gene mutations, leading to vitamin D resistance, treatable with high calcium doses, but alopecia remains permanent.

5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.

The new formulation greatly improved quercetin absorption in rats.

Oral 5-alpha-reductase inhibitors for hair loss don't increase heart risk.

Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.

Tocilizumab might be an effective treatment for COVID-19.

Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.

YWS1903 is safe for pregnant rats at moderate doses but causes fetal issues at high doses.